Hemodialysis patients. Renal failure
Conditions
Interventions
Intervention 1: Intervention group: N - Acetylcysteine with trade name of mucomyst, as 600 milligram tablet, made by swiss zambon company, given twice daily (every 12 hours), per oral for 6 weeks. Int
Treatment - Drugs
Placebo
Intervention group: N - Acetylcysteine with trade name of mucomyst, as 600 milligram tablet, made by swiss zambon company, given twice daily (every 12 hours), per oral for 6 weeks.
control group : Placebo 600 mg twice daily ( per 12 hours ) oral use, at a duration of 6 weeks
Sponsors
Vice Chancellor for Development, Research and Technology of Ahvaz Jondishapour University of Medica
Eligibility
Sex/Gender
All
Age
16 Years to 100 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: All of the chronic hemodialysis patients due to end stage renal disease more than 16 years old and at least three months has been past from starting of hemodialysis. Exclusion criteria: Every acute disease leads to hospitalization from one month before or during trial ; Allergy to N-acetylcysteine; Hepatic cirrhosis; Using vitamin E or C or every known antioxidant from 2 weeks before or during trial; Congestive heart failure or ejection fraction less than 35%; Not using of N- acetylcysteine or placebo more than 20% of total drug.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hemoglobin. Timepoint: Before intervention and 6 weeks after intervention. Method of measurement: by cyanmet hb method as gr/dl with drabkin kit.;Hematocrit. Timepoint: Before intervention and 6 weeks after intervention. Method of measurement: By Santrifiuj micro hematocrit as persentage. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactBabak Alavian
Ahvaz Jondishapour University of Medical Sciences
Outcome results
None listed